Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis
- PMID: 29218626
- DOI: 10.1007/s12094-017-1816-x
Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis
Abstract
The assessment of response to therapy in glioblastoma remains a challenge, because the surrogate measures of survival are subject to radiographic misinterpretation. A solid and reliable definition of progression is needed for both clinical decision-making and for evaluating response within the clinical trials. Historically, assessment criteria have used radiologic and clinical features aimed to correctly classify patients into progressive or non-progressive disease. The widely used RANO criteria are a valuable tool in disease evaluation, both in the clinical setting and in the clinical trials. However, assessment criteria have certain limitations that emerging image techniques have tried to overcome. Differentiating true progression from treatment-related changes (like pseudoprogression or pseudoresponse) is crucial in order not to prematurely discontinue adjuvant chemotherapy or redirect the patient to second-line options. This fact underscores the need for advanced radiologic techniques, like specific diffusion and perfusion MRI sequences, MR spectroscopy and PET, which seem to play a role in distinguishing these phenomena.
Keywords: Assessment criteria; Glioblastoma; Pseudoprogression; Pseudoresponse; RANO criteria; Radionecrosis.
Similar articles
-
Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.Radiol Clin North Am. 2019 Nov;57(6):1199-1216. doi: 10.1016/j.rcl.2019.07.003. Epub 2019 Aug 16. Radiol Clin North Am. 2019. PMID: 31582045 Review.
-
Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.Neuroimaging Clin N Am. 2021 Feb;31(1):103-120. doi: 10.1016/j.nic.2020.09.010. Neuroimaging Clin N Am. 2021. PMID: 33220823 Review.
-
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.Neurotherapeutics. 2017 Apr;14(2):307-320. doi: 10.1007/s13311-016-0507-6. Neurotherapeutics. 2017. PMID: 28108885 Free PMC article. Review.
-
Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.BMC Med Imaging. 2017 Feb 1;17(1):10. doi: 10.1186/s12880-017-0183-y. BMC Med Imaging. 2017. PMID: 28143434 Free PMC article. Clinical Trial.
-
Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.J Neurooncol. 2017 Sep;134(3):495-504. doi: 10.1007/s11060-017-2375-2. Epub 2017 Apr 5. J Neurooncol. 2017. PMID: 28382534 Free PMC article. Review.
Cited by
-
The Neurogenome study: Comprehensive molecular profiling to optimize treatment for Danish glioblastoma patients.Neurooncol Adv. 2023 Nov 2;5(1):vdad137. doi: 10.1093/noajnl/vdad137. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 38089638 Free PMC article.
-
Hemodynamic Imaging in Cerebral Diffuse Glioma-Part A: Concept, Differential Diagnosis and Tumor Grading.Cancers (Basel). 2022 Mar 10;14(6):1432. doi: 10.3390/cancers14061432. Cancers (Basel). 2022. PMID: 35326580 Free PMC article. Review.
-
Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme.Molecules. 2019 Jul 8;24(13):2496. doi: 10.3390/molecules24132496. Molecules. 2019. PMID: 31288488 Free PMC article.
-
11C-methyl-L-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases.Br J Radiol. 2021 Sep 1;94(1125):20210275. doi: 10.1259/bjr.20210275. Epub 2021 Aug 18. Br J Radiol. 2021. PMID: 34233489 Free PMC article.
-
Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas.J Neurooncol. 2020 Jan;146(2):363-371. doi: 10.1007/s11060-019-03387-6. Epub 2020 Jan 4. J Neurooncol. 2020. PMID: 31902040
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical